Skip to content

Benztropine for the relief of acute non-traumatic neck pain – a randomised trial

In patients presenting to the emergency department with acute non-traumatic neck pain, does benztropine compared to placebo relieve pain

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12612000354886
Enrollment
30
Registered
2012-03-28
Start date
2012-05-01
Completion date
2014-07-01
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Patients present to the Emergency department with acute cervical muscle spasm and pain, which may be spontaneous in onset or related to non-traumatic twisting events. In lay speech this may be referred to as a ‘wry neck’. Conventional analgesics such as paracetamol, NSAIDs and oral opoids are the mainstay of treatment for wry neck, but often provide inadequate pain relief. Centrally acting anti-cholinergic drugs are used for the relief of pain/spasm from the chronic condition of idiopathic cervical dystonia and from drug induced dystonic reactions. The use of these drugs for acute spasmodic neck pain has been poorly studied. There is a single study in the literature assessing the centrally-acting anti-cholinergic drug benztropine (trade name cogentin) in the relief of pain and spasm from this condition. This is a case series of 5 patients with acute pain and spasm of the neck and demonstrated remarkable relief of pain and improvement in range of motion in all patients following an intra-muscular injection of benztropine. Our hypothesis is that IM benztropine will provide relief of neck pain and improve range of neck movement in patients presenting with wry neck. We aim to compare the effect of 2mg IM benztropine with placebo on pain scores and range of motion in patients presenting to the ED with wry neck.

Interventions

a single dose of 2mg by intra-muscular injection (IM) of benztropine (volume of 2ml) will be administered.

Sponsors

St George Hospital
Lead SponsorHospital

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
16 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

-Non-traumatic neck pain of <24 hours duration -Age 16-65

Exclusion criteria

-Use of drugs known to cause dystonic reactions in the 24 hours prior to the onset of pain (eg metoclopramide (maxalon), prochlorperazine (stemetil), promethazine (phenergan), haloperidol) -Clinical suspicion of a secondary cause for pain (eg neck-space infections, cervical osteomyelitis, discitis, epidural abscess, pathological cervical fractures, primary or secondary malignancies) -Past history of cervical spine fracture -Past history of chronic or recurrent neck pain -Past history of cervical spine surgery -Fever -Focal neurological deficit -Known allergy or adverse event to benztropine -Anti-coagulant medication (eg warfarin or enoxaparin) or clopidogrel -Known coagulation disorder (eg haemophilia) or platelet disorder (eg ITP, leukaemia, myelodysplastic disorder) -Parkinsons disease -Schizophrenia -Pregnant women

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026